Cargando…

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

OBJECTIVES: Methotrexate is considered to be first-line therapy for rheumatoid arthritis (RA). However, a substantial proportion of treated patients do not achieve the desired goals of therapy. This analysis aimed to identify predictors of insufficient response to methotrexate in patients with early...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, van Vollenhoven, Ronald F, Florentinus, Stefan, Chen, Su, Suboticki, Jessica L, Kavanaugh, Arthur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225797/ https://www.ncbi.nlm.nih.gov/pubmed/30076156 http://dx.doi.org/10.1136/annrheumdis-2018-213502

Ejemplares similares

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
por: Smolen, Josef S, et al.
Publicado: (2013)

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
por: Smolen, J, et al.
Publicado: (2008)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
por: Strand, Vibeke, et al.
Publicado: (2011)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
por: Jones, G, et al.
Publicado: (2010)

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
por: Smolen, Josef S., et al.
Publicado: (2015)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
por: Salliot, C, et al.
Publicado: (2008)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
por: Tak, Paul P, et al.
Publicado: (2011)

Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
por: Kavanaugh, A, et al.
Publicado: (2008)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
por: O’Mahony, Alison, et al.
Publicado: (2018)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Pott's disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy
por: Zorlu, Mehmet, et al.
Publicado: (2013)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Methotrexate Hepatotoxicity in Patients with Rheumatoid Arthritis
por: Sotoudehmanesh, R, et al.
Publicado: (2010)

Adherence to Methotrexate therapy in Rheumatoid Arthritis
por: Arshad, Nasim, et al.
Publicado: (2016)

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
por: Humphreys, Jenny H, et al.
Publicado: (2017)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
por: Cohen, Stanley B, et al.
Publicado: (2010)

Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate
por: Fleischmann, Roy, et al.
Publicado: (2022)

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2017)

Modifications in Lipid Levels Are Independent of Serum TNF-α in Rheumatoid Arthritis: Results of an Observational 24-Week Cohort Study Comparing Patients Receiving Etanercept Plus Methotrexate or Methotrexate as Monotherapy
por: Rodriguez-Jimenez, Norma Alejandra, et al.
Publicado: (2014)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fee2fanat8r9f22mo9hffs99p6